Kornimate/medical-research-clean huggingface dataset:
ultrasound-guided stellate ganglion block with botulinum

Conditions: Change From Baseline House-Brackmann

Summary: the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (sgb) botulinum toxin on referactory facial nerve palsy

:idiopathic facial nerve palsy (bell's palsy) is caused by damage to the facial nerve at any site of the peripheral branches after the facial nucleus.stellate ganglion block is inteneded to increase blood flow and promotes nerve regeneration. the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (sgb) botulinum toxin on referactory facial nerve palsy

Eligibility criteria:
inclusion criteria: * diagnosed by clinical and neurological assessment as one-sided idiopathic facial palsy * age 18 to 60 •-asa i-ii exclusion criteria: * exclusion criteria: * diabetic * coagulation dysfunction * mental or cognitive dysfunclion * allergy to injected medication
effects of telemonitoring and telemedicine service for type 2 diabetes care

Conditions: Type 2 Diabetes

Summary: a multi-center, randomized, parallel, interventional, open label trial to compare hemoglobin a1c-lowering effect of conventional treatment and smart care service in patients with type 2 diabetes.

1. objectives : to evaluate superiority in the hemoglobin a1c -lowering effect of smart care service compared to the conventional treatment in patients with type 2 diabetes. 2. test and control group * control group : the subject group who is receiving any conventional treatment (hospital visit). * test groups * conventional treatment + remote monitoring group: the subject group who is receiving the health care services using conventional treatment (hospital visit) and remote monitoring. * remote visit + remote monitoring group: the subject group who is receiving remote visit and remote monitoring using videotelephony 3. target subject: type ii diabetes patients

Eligibility criteria:
inclusion criteria: 1. more than 20 years of age and under 60 years of age 2. patients who are able to receive outpatient treatment with type ii diabetes mellitus. 3. if the patients require using insulin, patients who are using basal insulin or premixed insulin less than 2 times a day are eligible. 4. patients with hba1c above 7% and less than 11% (7%≤hba1c≤11%). 5. patients who are able to understand the purpose of this trial and to read and write. 6. patients who are able to use the smart care pc for this study. 7. patients who have wired/wireless internet access at home. 8. patients who participate voluntarily and sign the informed consent. exclusion criteria: 1. patients with type i diabetes mellitus 2. patients who are using bolus insulin (short-acting insulin) or insulin pump. 3. patients who take medicines which can significantly affect glycemic control. 4. patients with acute illness, untreated other disease or diabetic complications required additional treatment. 5. patients currently being hospitalized or planning to hospitalize during the study period. 6. patients who have severe renal disease (above 1.5 times the upper limit of normal serum creatinine levels). 7. pregnant or lactating women. 8. patients with any severe liver disease including cirrhosis (ast or alt: above 3 times the upper limit of normal). 9. patients with uncontrolled chronic lung disease. 10. patients with known history of alcoholism, mental illness, or drug dependency. 11. patients who have cognitive disorder or psychiatric problems 12. patients who have participated in other clinical trial within 12 weeks prior to screening visit. 13. any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.

Keywords: telemonitoring usual care telemedicine telehealth home care health care quality access evaluation
heat therapy to reduce pain and improve walking tolerance

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study is to investigate whether exposure to heat therapy improves calf muscle oxygenation and enhances walking tolerance in patients with symptomatic peripheral arterial disease (pad).

heat therapy (ht) is an emerging non-invasive approach that has been shown to enhance vascular function of the leg in old individuals. the objective of this study is to establish evidence to support the validity of ht in improving walking tolerance on pad patents. subjects will complete baseline assessments for eligibility, including medical history and ankle-brachial measurement. eligible participants will be asked to report to the laboratory on 4 different occasions. the purpose of visits 1 and 2 the central hypothesis of this study, based on preliminary data, is that exposure to ht will enhance the oxygenation of calf muscles during exercise and as a result, the onset of pain will be delayed and walking performance will be enhanced. is to familiarize the participants with the treadmill walking test and assess the test-retest reliability of maximal walking time determination. on visits 3 and 4 participants will receive either heat treatment or a control treatment for 80 min prior to undergoing a symptom-limited incremental test on the treadmill.

Eligibility criteria:
inclusion criteria: * men and women with stable symptomatic leg claudication for 6 months or longer. * ankle brachial index \< 0.9 exclusion criteria: * heart failure * copd * critical limb ischemia * prior amputation * exercise-limiting co-morbidity * recent infrainguinal revascularization or planned during study period * plans to change medical therapy during duration of the study * active cancer * chronic kidney disease * hiv positive, active hbv or hcv disease * presence of any unsuitable comorbid clinical condition in the opinion of the pi * peripheral neuropathy, numbness or paresthesia in the legs * morbid obesity, bmi \> 36 or unable to fit in water-circulating pants * open wounds or ulcers on the extremity * unable to walk on the treadmill
compassionate use of regn-cov2 for the treatment of covid-19

Conditions: COVID-19

Summary: compassionate use requests will be considered for individuals who test positive for sars-cov-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.

compassionate use requests are only being considered in response to individual patient investigational new drug (ind) applications.

Eligibility criteria:

Keywords: post-exposure
twin a breech external cephalic version intervention trial (twexit)

Conditions: Breech Presentation; Twin; Complicating Pregnancy

Summary: a prospective study assessing the use of external cephalic version for the management of twin a breech presentation in twin pregnancy.

the primary goal of the study is to determine the success rate of twin a external cephalic version in our obstetric clinic and to determine new favorable sonographic criteria associated with a successful attempt that have not been investigated before.

Eligibility criteria:
inclusion criteria: * presence of the written consent of the patients. * the patients must be over 18 years old . * no limit in the ability to consent. exclusion criteria: * age under 18 * limited ability to consent * placenta previa * fetal abnormalities
management modalities of chronic pelvic pain

Conditions: Pain, Chronic

Summary: chronic pelvic pain remains a challenging disorder to treat because of the complexities of pain sensation and unclear etiology. standard medical and surgical treatments seldom prove effective at improving quality of life and pain intensity among affected women.

chronic pelvic pain remains a challenging disorder to treat because of the complexities of pain sensation and unclear etiology. standard medical and surgical treatments seldom prove effective at improving quality of life and pain intensity among affected women. the current study will investigate whether laparoscopic presacral neurectomy or fluoroscopically guided superior hypogastric plexus neurolysis is more effective for treating chronic pelvic pain.

Eligibility criteria:
inclusion criteria: * patient acceptance. * body mass index \< 35 kg/m2. * adult patients with chronic pelvic and perineal pain due to pelvic cancer. * visual analog scale pain score ≥ 5 on a 0-10 scale despite treatment with a standard analgesic. exclusion criteria: * uncooperative patient. * patients with coagulopathy, infection at the site of injection, severe cardiac compromise, or intolerance to sympathetic block.
safety study of a vaccine (denv-1 piv) to prevent dengue disease

Conditions: Dengue Fever

Summary: this is a phase 1 study to evaluate the safety of a vaccine (denv-1 piv) for the prevention of dengue fever.

denv infections can cause self-limited but incapacitating acute illness lasting four to seven days. the illness is characterized by fever, headache, severe pain in muscles, joints, pain behind the eyes, and a rash. denv infection can be complicated by the development of hemorrhagic fever (dhf) or shock syndrome (dss), which is manifested by plasma leakage and a bleeding diathesis or frank hemorrhage. dhf is fatal in at least 0.5% of pediatric cases but rarely in adults. people, particularly children, living in hyper-endemic areas who have antibodies from an earlier dengue infection with one serotype are at increased risk for dhf if subsequently infected by another dengue virus serotype. currently, no specific anti-viral therapy exists. therapy is largely supportive. mosquito control has failed to prevent dengue transmission; therefore, prevention of dengue through vaccination is an important objective of the world health organization (who) and many national governments, including the united states.

Eligibility criteria:
inclusion criteria: * males and females 18 years of age or the legal age of consent (whichever is greater) to 50 (inclusive) years of age * negative screening laboratory test against dengue, japanese encephalitis, west nile, and yellow fever viruses * healthy * all subjects must agree to use contraception or to abstain from sex from enrollment through trial completion * able to provide informed consent and able to be followed throughout the trial period exclusion criteria: * history of flavivirus infection or history of flavivirus vaccine (experimental or licensed product) including japanese encephalitis, west nile virus, yellow fever, and dengue * have a known or suspected hypersensitivity or adverse reaction to vaccines * have received a live-attenuated vaccine within 42 days prior to the initial injection on day 0 or a subunit or killed vaccine within 30 days of the initial injection on day 0 * are pregnant or breastfeeding * known hiv, hepatitis b and/or hepatitis c infection * have any acute illness, including an oral body temperature greater than 100.4°f at the day of vaccination * have any occupational, social, or medical concerns that would impact subject safety, interfere with protocol adherence, or affect a subject's ability to give informed consent * have been using immunomodulatory therapy (use of systemic corticosteroids or chemotherapeutics that may influence antibody development) within the past 6 months; medications or nutritional supplements known to or which potentially could affect organ function within 30 days prior to the initial injection * have received an investigational drug or vaccine or participated in a drug product or vaccine study within a period of 30 days prior to day 0 * have received or donated blood or plasma within 90 days of day 0 (or plan on receiving or donating blood or plasma during the study)

Keywords: dengue dengue fever monovalent dengue vaccine
text messaging to improve hiv testing among young women in kenya

Conditions: HIV Infection

Summary: the purpose of this study is to determine whether regularly scheduled hiv sensitization text messages (sms) are effective in increasing hiv testing rates among young women in kenya.

in kenya, women have higher rates of infection (6.9%) than men (4.4%) and young women aged 15-24 years are over three times more likely to be infected than young men of the same age group. hiv testing and counseling remains critical to identifying new infections and preventing the spread of hiv but many young women do not test and still continue to engage in high risk behavior. hiv programs have begun to leverage mobile phones and text messages to increase the reach and scale of interventions. kenya currently has 32.2 million mobile phone subscribers, representing a 79.2% country penetration. text messages have been used successfully in kenya for marketing purposes and have even been demonstrated to increase antiretroviral (art) adherence. despite advances in mobile-based applications to improve issues in health, none of these health applications have yet been able to reach the scale of mobile phone-based financial products in kenya. given the potential synergies of text message use and need for hiv testing, a randomized quasi-experimental study was conducted to test whether weekly text messages encouraging hiv testing and improving hiv awareness would increase hiv testing, enhance hiv risk perception and reduce high risk behaviour among young women 18-24 years old in a predominantly rural region in kenya. women in the intervention arm received access to a suite of hiv sensitization text messages sent weekly to increase their awareness of hiv and encourage them to test with the option of texting back for more information to a maximum of three times per week. women in the control arm did not receive these messages. all women were followed up for six months with monthly sms surveys collecting data on their hiv testing practices, sexual behaviour and risk perception.

Eligibility criteria:
inclusion criteria: * own a mobile phone which they don't share and which operates on a telecom provider supported by our sms platform * be hiv uninfected (by self report) or not know their hiv status * report not having tested for hiv in the preceding 12 months * know how to send and receive sms * must consent to the study * have regular access to electricity for charging a cell phone exclusion criteria: * did not consent to the study * did not meet inclusion criteria

Keywords: sms text messages young women hiv
assessing refractoriness and infectious survival events in aml

Conditions: Acute Myeloid Leukemia (AML)

Summary: despite therapeutic advance in acute myeloid leukemia (aml), the prognosis remains poor, with an overall survival (os) of 30% at 5 years \[1, 2\]. treatment of 1st-line aml in patients under 75 years of age is based on intensive chemotherapy (ic) followed by allogeneic transplantation (hematopoietic stem cell transplantation, hsct) \[3\]. following its administration, a phase known as aplasia ensues, during which patients are severely immunocompromised. this period of aplasia therefore carries a very high risk of infectious events, despite management in protected areas and infectious prophylaxis. infectious problems remain one of the leading causes of mortality in the initial phase of aml treatment \[4\]. the incidence of sepsis, the microorganisms involved and the complications arising from infectious episodes during chemotherapy remain poorly described, as do their long-term prognostic consequences for these patients \[5,6\]. moreover, there is a "dogma" among hematologists dealing specifically with aml that intensive chemotherapy during which there are no infectious events is often a sign of non-response. although this "popular" belief has never been verified prospectively or even retrospectively, it is based on the observation of many generations of clinicians. this belief suggests that immune stimulation during aplasie could promote remission by inducing an anti-leukemic immune response. furthermore, numerous cases of "spontaneous" remission (i.e. in aml patients receiving no active treatment) following infections or highly immune-stimulating events have been reported in the literature \[7-10\]. it might therefore be hypothesized that infectious events occurring during the post-intensive chemotherapy aplasia phase for aml could favor the achievement of remission by nonspecific immune stimulation. the aim of this study is to describe the incidence and type of septic episodes occurring in patients undergoing intensive treatment for acute myeloid leukemia, and to assess the impact of these episodes on patient prognosis, notably via the risk of relapse and long-term survival.


Eligibility criteria:
inclusion criteria: * patients with acute myeloid leukemia (aml) * age over 18 years * treatment with "intensive" chemotherapy (combination of aracytin and an anthracycline) * date of diagnosis of acute myeloid leukemia between 01/01/2015 and 31/12/2021 * treatment received at hospices civils de lyon (hcl) exclusion criteria: * patients with acute promyelocytic leukemia (aml 3) * treatment with "non-intensive" chemotherapy (i.e. azacytidine) * death before first post-chemotherapy bone marrow assessment * no computerized data available * follow-up at a center other than hcl

Keywords: acute myeloid leukemia infections intensive chemotherapy survival
image-guided brachytherapy for vaginal cancer (embrave)

Conditions: Vaginal Neoplasms

Summary: the goal of this clinical study is to improve clinical outcomes of patients with vaginal cancer who are treated with curative intent by primary radio(chemo)therapy and image-guided adaptive brachytherapy (igabt). being an observational, prospective registration study, wherein neither an experimental treatment is compared to the standard treatment, nor groups of patients are compared. the specific aims are: * to develop evidence-based recommendations for curative intent treatment with primary radio(chemo)therapy and igabt. * to identify prognostic parameters for oncological outcomes, morbidity and quality of life. the study aims to enroll at least 300 patients. oncological events will be evaluated at 2 and 5 years of follow-up. acute and late morbidity events will be evaluated at end of treatment, 2 and 5 years of follow-up.


Eligibility criteria:
inclusion criteria: * histologically proven primary vaginal cancer or carcinoma in situ, per who classification * histological types: main cohort: squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the vagina; parallel cohort: other epithelial carcinomas and carcinoma in situ/vaginal intraepithelial neoplasia, as per who classification * primary vaginal cancer are treated following the protocol target concept. * primary vaginal cancer: stage i-iva; para-aortic lymph node metastasis below l1-l2 interspace are allowed * planned igabt treatment with mri-guided adaptive brachytherapy (at least the 1st fraction contouring and planning on mri; ct for later fractions is allowed); main cohort: external beam radio(chemo)therapy followed by igabt; parallel cohort igabt alone * igabt alone for stage i \<2 cm or carcinoma in situ will be registered in a parallel cohort in this study * treatment with curative intent * written informed consent exclusion criteria: * vaginal cancers with involvement of the ostium of the cervix or vulva (these should be classified as cervical cancer or vulvar cancer, respectively) * metastatic disease beyond para-aortic region l1-l2 interspace * sarcomas and melanomas. * treatment only by external beam radiotherapy * treatment by primary surgery or debulking surgery * treatment with neo-adjuvant radiotherapy and/or neo-adjuvant chemotherapy followed by surgery * treatment including neo-adjuvant or adjuvant chemotherapy * previous pelvic or abdominal radiotherapy * pregnancy
observational pilot study with tachosil as a ventricular sealant

Conditions: Intraventricular Neoplasm

Summary: the working hypothesis in this study is that after entering the cerebral ventricular system the sealing with tachosil is effective and safe. a more specific hypothesis is that the use of tachosil for brain surgery with ventricular entry reduces the number of postoperative complications (hydrocephalus, csf leak, meningitis and pseudomeningocele).

pilot observational study with medications (moe), single-center, prospective and retrospective study with a group of patients operated on for periventricular lesions and with ventricular entry. as it is an infrequent type of surgery in our centre, the study includes a retrospective group (same surgery and use of tachosil). primary objectives: the main objective of the study is to evaluate the effectiveness and safety of tachosil in patients who require ventricular entry. to evaluate the effectiveness, the percentage of complications related to the ventricular entry during surgery are recorded. these complications are hydrocephalus, csf leak, meningitis, and pseudomeningocele. secondary objectives * intraoperative incidence of fistula after application of the ventricular patch at 20cm peep h20 (efficacy objective). * incidence of clinically confirmed percutaneous fistula during the first 30 days after surgery (efficacy objective). * incidence of pseudomeningocele \>20cc confirmed with mri or ultrasound (effectiveness objective). * incidence of radiologically confirmed hydrocephalus during the first 90 days after of the surgery. * record the percentage of use of other dural sealants * evaluate the cost effectiveness of the product. * describe the adverse effects related to the product * incidence of complication requiring reintervention within 30 days to the main surgery (safety objective). * assessment of the complications that are avoided: readmissions. study period: from december 2020 to december 2023.

Eligibility criteria:
inclusion criteria: * patients who are candidates for elective supratentorial surgery (tumoral, vascular or epilepsy) that during the procedure present ventricular entry, being sealed by a patch of tachosil * ventricular entry during the procedure (intraoperative csf outflow from the ventricle noticed by the surgeon) * adults over the age of 18 * informed consent signed by the patient or representative (see annex 2). for cases in which the patient has died during this time a waiver of consent will be requested. exclusion criteria: * patients or representatives who do not want to sign the consent are excluded informed, pregnant women or those under 18 years of age.

Keywords: ventricle opening ventricular entry complication pseudomeningocele cerebrospinal fluid leakage meningitis